IMDX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Insight Molecular Diagnostics Inc (IMDX) is not a strong buy for a beginner, long-term investor at this moment. While there are positive developments such as the FDA submission for GraftAssureDx and a secured cash position, the company's financial performance is weak, technical indicators are bearish, and there are no strong trading signals or significant insider/hedge fund activity. It is better to monitor the stock for further developments, such as FDA approval or improved financials, before considering an entry.
The technical indicators for IMDX are bearish. The MACD histogram is below 0 and negatively contracting, RSI is neutral at 49.658, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 3.533, with key resistance at 4.316 and support at 2.75.
FDA submission for GraftAssureDx, which could act as a major catalyst upon approval.
Completion of a $26 million capital raise, securing cash for operations and growth.
Progress in onboarding transplant centers, with 28 centers already in the registry process.
Weak financial performance in Q4 2025, with revenue, net income, and EPS all showing significant YoY declines.
Challenges in clinician adoption despite demand for heart transplant testing.
Low lab services revenue expected in 2026.
In Q4 2025, the company reported a revenue drop of -23.35% YoY to $1,139,000, a net income drop of -31.50% YoY to -$22,955,000, and an EPS drop of -62.50% YoY to -0.72. However, gross margin improved by 8.77% YoY to 43.55%.
Lake Street raised the price target to $12 from $8 and maintained a Buy rating, citing the secured cash position and the potential FDA approval for GraftAssureDx as key catalysts.
